Advertisement
MEDP vs TMO
Which Stock Would AI Choose? Medpace Holdings (MEDP) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- MEDP is a focused clinical contract research organization (CRO) serving biotech and pharmaceutical sponsors, while TMO is a diversified life sciences tools and services leader.
- Both stocks have posted strong recent momentum, but their scale, business mix, and growth drivers differ materially.
- MEDP has drawn a wave of analyst price-target increases but holds a consensus "Hold" rating, reflecting valuation debate after its rally.
- TMO carries a stronger "Strong Buy" consensus and is advancing through targeted acquisitions and product innovation.
- Relative performance and market positioning favor TMO on stability and diversification, while MEDP offers higher growth orientation with higher beta.
Introduction
Investors evaluating the healthcare and life sciences sector often weigh high-growth specialists against diversified industry leaders. This stock comparison examines MEDP (Medpace Holdings) and TMO (Thermo Fisher Scientific) to help traders and investors assess their relative performance and market positioning. Although both companies operate in the broader drug development ecosystem, they serve different roles and risk profiles. This analysis is relevant for investors comparing a mid-cap CRO focused on clinical trials with a large-cap scientific instruments and services conglomerate, and for those seeking insight into how trend, stability, and catalysts may shape near-term outcomes.
MEDP Overview and Recent Performance
Medpace Holdings is a clinical contract research organization (CRO) that provides outsourced drug and medical device development services, spanning clinical monitoring, regulatory affairs, data management, and laboratory support for biotechnology, pharmaceutical, and medical device sponsors. The company is headquartered in Cincinnati and operates across North America, Europe, and Asia.
In recent weeks, MEDP shares have traded in the low-to-mid $600 range, with a market capitalization near $17 billion and a price-to-earnings (P/E) ratio in the mid-30s. Recent market activity reflects improving sentiment tied to a recovery in biotech funding and stabilizing CRO demand, alongside several analyst price-target increases from firms including Mizuho, Barclays, RBC Capital, and UBS. Despite this, the consensus rating sits at "Hold," indicating that much of the optimism may already be reflected in the share price after a substantial run. Investors are watching forward bookings, backlog trends, and the company's upcoming earnings report as key catalysts.
TMO Overview and Recent Performance
Thermo Fisher Scientific is a global leader in life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services, including its PPD clinical research business. The company serves pharmaceutical, biotech, academic, government, and industrial customers worldwide, with a market capitalization exceeding $200 billion.
TMO shares have rallied meaningfully in recent months, recently trading near multi-year highs. The company has reported solid revenue and adjusted earnings per share (EPS) growth, supported by strength in bioproduction and clinical research, and has raised its full-year financial guidance. Strategic moves such as the acquisition of Clario, a digital endpoint data solutions provider, and the divestiture of its microbiology business have reshaped its portfolio toward higher-value areas. Analysts maintain a largely "Strong Buy" consensus, though some caution that valuation now factors in much of the expected recovery.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page curates a selection of AI trading bots suited to current market conditions. Tickeron operates hundreds of AI Trading Bots that trade thousands of different tickers, yet only the strongest performers earn a place in this curated section. Each bot has its own trading style, strategy, timeframe, performance statistics, and set of tickers it trades, so the collection spans approaches ranging from short-term momentum to longer-horizon trend following. The platform highlights key metrics so users can evaluate bots based on historical win rates, trade frequency, and volatility-adjusted returns. Exploring the Trending AI Robots page can help investors identify automated strategies aligned with their own risk preferences.
Head-to-Head Comparison
The two companies differ most sharply in scale and diversification. MEDP is a mid-cap pure-play CRO with a beta above 1.0, meaning its price tends to move more than the broader market and is highly sensitive to biotech funding cycles. TMO is a diversified large-cap with multiple revenue streams that smooth out cyclicality, though it remains exposed to academic, government, and diagnostics spending softness and to foreign-exchange and tariff pressures.
On growth drivers, MEDP depends on clinical trial bookings and biotech capital availability, while TMO benefits from broader secular trends in scientific instrumentation, bioproduction, and AI-enabled workflows. In terms of recent momentum, both have advanced strongly, but TMO's rally has been reinforced by earnings beats and raised guidance, whereas MEDP's move has been driven more by sentiment and analyst revisions. Risk factors also diverge: MEDP carries concentration and valuation risk, while TMO faces integration and macroeconomic risks. Market sentiment currently assigns TMO a stronger consensus rating and greater institutional stability, while MEDP offers higher growth potential at a smaller scale.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings momentum, and relative positioning, Tickeron's AI would likely favor TMO in the current environment. The stock has demonstrated more consistent upward trend confirmation, supported by consecutive earnings beats, raised guidance, and a stronger analyst consensus. MEDP, by contrast, shows robust momentum but also higher volatility and a more contested valuation picture, suggesting its trend is somewhat less stable. That said, this assessment is probabilistic rather than definitive, and relative positioning could shift quickly if either company's upcoming catalysts alter the trend.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEDP is a Hold and TMO is a StrongBuy.
MEDP's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for MEDP turned positive on October 15, 2026. Looking at past instances where MEDP's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on MEDP as a result. In 76 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
MEDP moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDP advanced for three days, in 237 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 192 of 255 cases where MEDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for MEDP moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 25 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
MEDP broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MEDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (41.946) is normal, around the industry mean (67.473). P/E Ratio (37.580) is within average values for comparable stocks, (2.957). Projected Growth (PEG Ratio) (2.929) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.390) is also within normal values, averaging (9.775).
TMO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TMO turned positive on October 28, 2026. Looking at past instances where TMO's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TMO as a result. In 58 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 132 of 244 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 19 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.892) is normal, around the industry mean (67.473). P/E Ratio (37.453) is within average values for comparable stocks, (2.957). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
MEDP | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 38 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 19 | 66 | |
SMR RATING 1..100 | 11 | 60 | |
PRICE GROWTH RATING 1..100 | 38 | 10 | |
P/E GROWTH RATING 1..100 | 54 | 25 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (65) in the Medical Specialties industry is in the same range as MEDP (83) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to MEDP’s over the last 12 months.
MEDP's Profit vs Risk Rating (19) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (66) in the Medical Specialties industry. This means that MEDP’s stock grew somewhat faster than TMO’s over the last 12 months.
MEDP's SMR Rating (11) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (60) in the Medical Specialties industry. This means that MEDP’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's Price Growth Rating (10) in the Medical Specialties industry is in the same range as MEDP (38) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to MEDP’s over the last 12 months.
TMO's P/E Growth Rating (25) in the Medical Specialties industry is in the same range as MEDP (54) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to MEDP’s over the last 12 months.
| MEDP | TMO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 69% | 1 day ago 53% |
| Stochastic ODDS (%) | 1 day ago 64% | 1 day ago 62% |
| Momentum ODDS (%) | 1 day ago 77% | 1 day ago 66% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 60% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 63% |
| Advances ODDS (%) | 5 days ago 75% | 2 days ago 62% |
| Declines ODDS (%) | 1 day ago 63% | 8 days ago 62% |
| BollingerBands ODDS (%) | 1 day ago 64% | 1 day ago 57% |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 54% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MEDP’s FA Score shows that 2 FA rating(s) are green while TMO’s FA Score has 2 green FA rating(s).
- MEDP’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MEDP’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- MEDP’s TA Score: 5 bullish, 4 bearish.
- TMO’s TA Score: 4 bullish, 4 bearish.
Price Growth
MEDP (@Medical Specialties) experienced а -2.57% price change this week, while TMO (@Medical Specialties) price change was +3.44% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.12%. For the same industry, the average monthly price growth was -4.89%, and the average quarterly price growth was +48.45%.
Reported Earning Dates
MEDP is expected to report earnings on Feb 15, 2027.
TMO is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Medical Specialties (+2.12% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with TMO. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | -3.77% | ||
| TMO - MEDP | 61% Loosely correlated | -1.72% | ||
| CRL - MEDP | 57% Loosely correlated | -4.44% | ||
| A - MEDP | 44% Loosely correlated | -3.47% | ||
| RVTY - MEDP | 44% Loosely correlated | -5.30% | ||
| BRKR - MEDP | 43% Loosely correlated | -7.95% | ||
More | ||||